scholarly article | Q13442814 |
P50 | author | Seda Baykal | Q59691178 |
Ahmet S Yavuz | Q84704815 | ||
Öykü Gönül Geyik | Q89919169 | ||
Zeynep Yüce | Q89919173 | ||
P2093 | author name string | Halil Ateş | |
Osman Uğur Sezerman | |||
Güner Hayri Özsan | |||
Eda Acikgoz | |||
P2860 | cites work | The basics of epithelial-mesenchymal transition | Q24652992 |
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options | Q27028181 | ||
CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells | Q28084610 | ||
Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization | Q28118751 | ||
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression | Q28595042 | ||
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML | Q29614278 | ||
Molecular requirements for epithelial-mesenchymal transition during tumor progression | Q29618960 | ||
Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2 | Q33686871 | ||
The molecular biology of chronic myeloid leukemia. | Q34079452 | ||
Specific targeted therapy of chronic myelogenous leukemia with imatinib | Q34215244 | ||
Monitoring response and resistance to treatment in chronic myeloid leukemia | Q34761663 | ||
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back | Q35128883 | ||
Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells | Q35814987 | ||
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation | Q36130255 | ||
The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. | Q36182260 | ||
Genetic and epigenetic regulators of pluripotency | Q36744480 | ||
Epigenetic reprogramming and induced pluripotency | Q37201452 | ||
Molecular biology of bcr-abl1-positive chronic myeloid leukemia | Q37283128 | ||
The Culture-Repopulating Ability assays and incubation in low oxygen: a simple way to test drugs on leukaemia stem or progenitor cells. | Q37290636 | ||
Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions | Q37673086 | ||
Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. | Q51181111 | ||
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. | Q51371803 | ||
Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. | Q52552851 | ||
Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine | Q61890299 | ||
Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease | Q61897325 | ||
Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction | Q68465559 | ||
Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells | Q72813175 | ||
The effects of growth factors on multicellular spheroids formed by chick embryonic retinal cells | Q73851749 | ||
Nilotinib | Q81561753 | ||
Hybrid epithelial/mesenchymal phenotype(s): The 'fittest' for metastasis? | Q89573631 | ||
Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications | Q37735627 | ||
CD44 in hematological neoplasias | Q37831812 | ||
Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. | Q38260649 | ||
The chronic myeloid leukemia stem cell: stemming the tide of persistence | Q38761787 | ||
Decreased Expression of Caveolin-1 and E-Cadherin Correlates with the Clinicopathologic Features of Gastric Cancer and the EMT Process | Q38799102 | ||
CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition | Q38980899 | ||
Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties | Q39117436 | ||
Epithelial-to-mesenchymal transition in tumor progression | Q39339887 | ||
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. | Q39370827 | ||
Targeting of CD44 eradicates human acute myeloid leukemic stem cells | Q40228130 | ||
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells | Q40228137 | ||
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia | Q40302552 | ||
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity | Q41356541 | ||
Induction of erythroid differentiation in the human leukaemia cell line K562. | Q43585129 | ||
Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. | Q44370532 | ||
Fibroblast growth factor-2 in serum-free medium is a potent mitogen and reduces dedifferentiation of human ear chondrocytes in monolayer culture. | Q45008815 | ||
Fully Dedifferentiated Chondrocytes Expanded in Specific Mesenchymal Stem Cell Growth Medium with FGF2 Obtains Mesenchymal Stem Cell Phenotype In Vitro but Retains Chondrocyte Phenotype In Vivo | Q49478142 | ||
E-cadherin: Its dysregulation in carcinogenesis and clinical implications. | Q49570064 | ||
Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. | Q49984629 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 2 | |
P921 | main subject | chronic myeloid leukemia | Q729735 |
myeloid leukemia | Q11688946 | ||
P304 | page(s) | e0229104 | |
P577 | publication date | 2020-02-27 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells | |
P478 | volume | 15 |
Search more.